富祥藥業(300497.SZ):祥太科學獲得他唑巴坦的化學原料藥上市申請批准通知書
格隆匯12月7日丨富祥藥業(300497.SZ)公佈,近日,江西富祥藥業股份有限公司全資子公司江西祥太生命科學有限公司(簡稱“祥太科學”)收到國家藥品監督管理局核准簽發的他唑巴坦原料藥《化學原料藥上市申請批准通知書》。
他唑巴坦是一種不可逆性競爭型β-內酰胺酶抑制劑,為第三代抗菌強增效劑,可以抑制β-內酰胺酶的活性,使酶活性不可逆轉,防止抗生素的敏感性降低,也可以儘量避免產生耐藥性並增加抗生素的抗菌活性。他唑巴坦能與多種β-內酰胺類抗生素產生協同作用,其與哌拉西林或頭孢哌酮合用可增強二者的藥效及延長作用時間。
注射用哌拉西林鈉他唑巴坦鈉為2020版國家醫保乙類及2018版國家基藥目錄品種。米內網數據顯示,2022年中國公立醫療機構終端哌拉西林鈉他唑巴坦鈉注射劑銷售額超過80億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.